Freek Verheul
Overview
Explore the profile of Freek Verheul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malpas C, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, et al.
Brain
. 2020 May;
143(5):1400-1413.
PMID: 32386427
Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years of symptom onset. Several...
2.
Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, et al.
Mult Scler
. 2019 Aug;
26(1):79-90.
PMID: 31397221
Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and paraclinical...
3.
Nguyen A, Kubala Havrdova E, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al.
Mult Scler Relat Disord
. 2019 Jan;
28:235-243.
PMID: 30623864
Background: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be increasing. Objective: To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes...
4.
Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, et al.
JAMA Neurol
. 2018 Aug;
75(11):1407-1415.
PMID: 30083762
Importance: The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) remains contested. Objective: To examine the association of superimposed relapses in progressive-onset MS...
5.
Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, et al.
Brain
. 2017 Oct;
140(9):2426-2443.
PMID: 29050389
Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response are lacking. Our...
6.
Rojas J, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, et al.
Mult Scler J Exp Transl Clin
. 2017 Jun;
1:2055217315600193.
PMID: 28607702
Methods: Centers from 18 countries with >20 cases enrolled in the MSBase Registry participated. Patients with MS with a disease duration of >1 year and <30 years at time of...
7.
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Signori A, Izquierdo G, Lugaresi A, Hupperts R, GrandMaison F, Sola P, et al.
Mult Scler
. 2017 Apr;
24(5):642-652.
PMID: 28382837
Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patients detected a consistent heterogeneity in the rate of disability accumulation. Objectives: To identify subgroups of PPMS patients with...
8.
Kalincik T, Brown J, Robertson N, Willis M, Scolding N, Rice C, et al.
Lancet Neurol
. 2017 Feb;
16(4):271-281.
PMID: 28209331
Background: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is...
9.
Spelman T, Meyniel C, Rojas J, Lugaresi A, Izquierdo G, GrandMaison F, et al.
Mult Scler
. 2016 Nov;
23(10):1346-1357.
PMID: 27885062
Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs)....
10.
Tao C, Simpson Jr S, van der Mei I, Blizzard L, Havrdova E, Horakova D, et al.
J Neurol Neurosurg Psychiatry
. 2016 Nov;
87(12):1343-1349.
PMID: 27810919
Background: Age at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what factors can influence AAO may shed light...